Applicant, as named in the Orange Book

Taiho Oncology

Next listed expiry: Lonsurf on 3 Feb 2037. 3 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Lonsurf · 2 strengths tipiracil hydrochloride; trifluridine	tipiracil hydrochloride; trifluridine	207981	3 Feb 2037	patent
Lytgobi futibatinib	futibatinib	214801	5 Nov 2039	patent
Inqovi cedazuridine; decitabine	cedazuridine; decitabine	212576	10 Dec 2042	patent, carve-out possible

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.